Twitxy Saved

Prof. Akiko Iwasaki

Verified account This account is verified. Learn more

@VirusesImmunity

We study antiviral immunity and viral disease pathogenesis. #COVID19 #longCOVID #vaccines @HHMINEWS @YaleIBIO @YaleMed @YaleCII
New Haven, CT medicine.yale.edu/lab/iwasaki/ Joined May 2017
1.9K Following 211K Followers 15K Posts

Latest posts 5

Prof. Akiko Iwasaki Verified account @VirusesImmunity
We are looking for a Scientific Program Manager for our new Neuroimmune Post-Acute Infection Syndrome Program 📣 We are seeking a PhD-level Scientific Program Manager to serve as the program's operational and administrative backbone. Please apply/spread the word 🙏🏼
🔬 We’re hiring! 🧬
Join our dynamic research team at the Yale Center for Infection and Immunity as a Scientific Program Manager! Help advance cutting-edge research and scientific discovery at Yale University.
🔗 Learn more and apply below: careers.yale.edu/us/en/job/YUCY…
View quoted post on X
11 replies 115 reposts 309 likes 18K views View on X
Prof. Akiko Iwasaki Verified account @VirusesImmunity
Grateful to @NPR for the chance to talk about how stress and infections like COVID can stir dormant viruses in our bodies, and what that may mean for our immune system. Still much to learn, and I’m thankful to my team and colleagues for their work 🎧 npr.org/2026/10/23/nx-…
www.npr.org The dormant viruses in all of us may help explain long COVID : Short Wave Virtually every human on Earth has a slew of different types of dormant viruses in our bodies. They are remnants of past infections and are—generally—harmless. Unless they wake up, which can be...
41 replies 474 reposts 1.4K likes 49K views View on X
Prof. Akiko Iwasaki Verified account @VirusesImmunity
Grateful to see the announcement of FLINTLOCK Phase 2 RCT with VYD2311 (monoclonal antibody against spike) in Long COVID and post-COVID vaccination syndrome. It will help us learn whether spike-directed therapies are helpful and for which patient subset
investors.invivyd.com/news-releases/…
investors.invivyd.com Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a... FLINTLOCK Phase 2 clinical trial will evaluate the safety, tolerability, pharmacokinetics, and clinical efficacy of high-dose monoclonal antibody VYD2311 in adults aged 18-65 years with Long COVID or...